trending

Imugene (ASX:IMU) shares up on ASX Here’s why?

Mar 23, 2022

Key Takeaways:

  • Imugene has received approval from Western Institutional Review Board to commence Phase I clinical trial of its VAXINIA.
  • The US component of the Stage I trial will be done under the FDA investigational new drug (IND) process.
  • The clinical trial is expected to run for 2 years, and will be financed from the current budget and resources.

On 23 March 2022, Imugene shares are trading up on ASX following the announcement about the commencement of Phase I clinical trial of its oncolytic virotherapy candidate, VAXINIA, in multiple solid tumors in patients. It has received approval from Western Institutional Review Board (WIRB).

At AEDT 3:38 PM, IMU shares are trading at AU$0.285, up 9.615% from the previous close.  

By submitting your details and clicking on the button above, you agree to our Terms and Conditions, Privacy Policy and consent to receive marketing offers including to be contacted by email or phone. Before continuing, please read the Financial Services Guide available here.

Recent News

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions

Allow cookies